Omeros (Germany) Performance
| 3O8 Stock | EUR 10.53 0.62 5.56% |
Omeros holds a performance score of 15 on a scale of zero to a hundred. The company holds a Beta of 0.48, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Omeros' returns are expected to increase less than the market. However, during the bear market, the loss of holding Omeros is expected to be smaller as well. Use Omeros market risk adjusted performance, semi deviation, coefficient of variation, as well as the relationship between the mean deviation and downside deviation , to analyze future returns on Omeros.
Risk-Adjusted Performance
15 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Omeros are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Omeros reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 10.5 M | |
| Total Cashflows From Investing Activities | 193.7 M |
Omeros |
Omeros Relative Risk vs. Return Landscape
If you would invest 375.00 in Omeros on September 2, 2024 and sell it today you would earn a total of 678.00 from holding Omeros or generate 180.8% return on investment over 90 days. Omeros is currently producing 1.961% returns and takes up 9.9135% volatility of returns over 90 trading days. Put another way, 88% of traded stocks are less volatile than Omeros, and 61% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Omeros Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Omeros' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Omeros, and traders can use it to determine the average amount a Omeros' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1978
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | 3O8 | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.91 actual daily | 88 88% of assets are less volatile |
Expected Return
| 1.96 actual daily | 39 61% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Omeros is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Omeros by adding it to a well-diversified portfolio.
Omeros Fundamentals Growth
Omeros Stock prices reflect investors' perceptions of the future prospects and financial health of Omeros, and Omeros fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Omeros Stock performance.
| Return On Asset | -0.36 | |||
| Operating Margin | 5.54 % | |||
| Current Valuation | 233.4 M | |||
| Shares Outstanding | 62.73 M | |||
| Price To Earning | (8.00) X | |||
| Price To Book | 8.23 X | |||
| Price To Sales | 4.82 X | |||
| EBITDA | (170.49 M) | |||
| Cash And Equivalents | 47.22 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 313.46 M | |||
| Debt To Equity | 902.60 % | |||
| Book Value Per Share | (0.74) X | |||
| Cash Flow From Operations | (109.72 M) | |||
| Earnings Per Share | (2.63) X | |||
| Total Asset | 419.27 M | |||
About Omeros Performance
By analyzing Omeros' fundamental ratios, stakeholders can gain valuable insights into Omeros' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Omeros has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Omeros has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system , and immune-related diseases. The company was incorporated in 1994 and is based in Seattle, Washington. OMEROS CORP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 236 people.Things to note about Omeros performance evaluation
Checking the ongoing alerts about Omeros for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Omeros help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Omeros is way too risky over 90 days horizon | |
| Omeros appears to be risky and price may revert if volatility continues | |
| Omeros has high likelihood to experience some financial distress in the next 2 years | |
| Omeros has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Omeros has accumulated about 47.22 M in cash with (109.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96. |
- Analyzing Omeros' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Omeros' stock is overvalued or undervalued compared to its peers.
- Examining Omeros' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Omeros' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Omeros' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Omeros' stock. These opinions can provide insight into Omeros' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Omeros Stock analysis
When running Omeros' price analysis, check to measure Omeros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omeros is operating at the current time. Most of Omeros' value examination focuses on studying past and present price action to predict the probability of Omeros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omeros' price. Additionally, you may evaluate how the addition of Omeros to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |